Pharmaceutical

AGC and Asahi partner for clinical drug production in Seattle

AGC has entered into an agreement with Asahi Kasei to produce clinical drug substance for antibody-based therapies at its Seattle site.

Aug 16, 2023 - 20:00
AGC and Asahi partner for clinical drug production in Seattle
AGC has entered into an agreement with Asahi Kasei to produce clinical drug substance for antibody-based therapies at its Seattle site.
Read the original article

Tags:

Previous Article

Signal: Illumina under investigation by SEC over $8bn Grail acquisition

Next Article

Precision and Imugene conclude transaction for cancer drug azer-cel

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer

BMS gains EMA validation for Opdivo/Yervoy combo in liv...

Jul 20, 2024

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

Health Canada issues NOC to J&J’s CARVYKTI for multiple...

Nov 23, 2024

Activist investor Starboard forges $1bn stake in Pfizer to swing profits

Activist investor Starboard forges $1bn stake in Pfizer...

Oct 8, 2024